How much passive income would a $10,000 investment in CSL shares generate?

Can this stock offer healthy dividends?

Owners of CSL Ltd (ASX: CSL) shares have benefited from enormous capital growth over the past decade, powered by its excellent profit growth in that time. This profit generation is enabling larger and larger passive income payouts.

I like dividends because they allow investors to benefit from growth in the value of the business without having to sell shares to access that value.

CSL is one of the biggest companies on the ASX, with a market capitalisation of $135 billion. While it is a massive business, can it provide the same sort of dividend income as National Australia Bank Ltd (ASX: NAB), Westpac Banking Corp (ASX: WBC) or Rio Tinto Ltd (ASX: RIO)?

Let's look at how much passive income a $10,000 investment could generate with CSL shares.

A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

Dividend potential of CSL shares

Dividends are paid for by the profit a company makes.

CSL's board decided to declare an FY23 final dividend of US$1.29 per share and a full-year dividend of US2.36 per share. Converted into Australian dollars, the total full-year dividend amounted to approximately A$3.59 per share, an increase of 13%. This came after the company generated net profit after tax (NPAT) of $2.19 billion in FY23.

The passive income growth continued in the FY24 first-half result, with the interim payout of US$1.19 per share. In Australian dollar terms, the half-year dividend was increased 12% to A$1.81.

The last two dividends paid by CSL amount to US$2.48 per share, or A$3.72 at the current exchange rate. That translates into a dividend yield of just 1.3%.

$10,000 investment

If I had $10,000 to invest in the ASX healthcare giant, I'd be able to buy 35 CSL shares.

Assuming CSL paid the same dividends over the next 12 months as the last 12 months, a shareholder would receive $130 of cash if they owned 35 CSL shares.

If its profit continues climbing, the company may be able to significantly increase its passive income in future financial years.

The broker UBS has forecast the company's dividend per share can increase to US$3.80 per share by FY28. If CSL did pay that amount, it would translate into a dividend yield of 2%, or around $200 in dollar terms.

While the prediction implies the CSL dividend could grow by more than 50% over the next four years, the dividend yield is still expected to be small by FY28.

CSL share price snapshot

Over the past year, the CSL share price has fallen more than 8%. According to UBS' profit projection, it's now trading at 30x FY24's estimated earnings.

Dividends may not be the most compelling reason to look at CSL shares, but its recovery from COVID-19 impacts and the product development pipeline could be more intriguing.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares on the slide today?

Big merger news isn't exciting investors just yet.

Read more »